Allogeneic hematopoietic cell transplant in HCV-infected patients.
Hepatitis C virus (HCV) is a major cause of liver disease worldwide. After allogeneic Hematopoietic Cell Transplant (HCT), HCV is known to be associated with transient hepatitis in the immediate post-transplant period, and a potential risk factor of veno-occlusive disease (SOS). Very recently, HCV-infected HCT recipients have been shown to be at higher risk of earlier cirrhosis, leading to greater morbidity and mortality. Long-term survivors after HCT are thus at a high risk for HCV-related complications and, as a consequence, the treatment of HCV infection becomes critical. We describe here the potential clinical complications in HCV-infected recipients, in the short, but also the long-term follow-up after HCT. The pathophysiology of liver fibrosis is discussed as well as the present recommended therapy in this particular population.
Peffault de Latour
Régis
R
Service d'Hématologie-Greffe, Hôpital Saint Louis, 75475 Paris, France. regis.peffaultdelatour@sls.aphp.fr
Ribaud
Patricia
P
Robin
Marie
M
Valla
Dominique
D
Marcellin
Patrick
P
Socié
Gérard
G
Asselah
Tarik
T
D018450:Disease Progression; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006526:Hepatitis C / Q000175:diagnosis / Q000453:epidemiology*; D006801:Humans; D008103:Liver Cirrhosis / Q000503:physiopathology / Q000821:virology; D012307:Risk Factors; D014184:Transplantation, Homologous / Q000009:adverse effects